Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma

被引：0
|
作者：
Asai, Katsunori
Narita, Yoshitaka
Nagane, Motoo
Mishima, Kazuhiko
Terui, Yasuhito
Arakawa, Yoshiki
Yonezawa, Hajime
Fukuhara, Noriko
Sugiyama, Kazuhiko
Shinojima, Naoki
Aoi, Arata
Nishikawa, Ryo
机构：
[1] Osaka Int Canc Inst, Dept Neurosurg, Osaka, Japan
[2] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan
[3] Kyorin Univ, Fac Med, Dept Neurosurg, Tokyo, Japan
[4] Saitama Med Univ Int Med Ctr, Dept Neurooncol Neurosurg, Saitama, Japan
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan
[6] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan
[7] Kagoshima Univ Hosp, Dept Neurosurg, Kagoshima, Japan
[8] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[9] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan
[10] Hiroshima Univ Hosp, Neurooncol Program, Hiroshima, Japan
[11] Kumamoto Univ Hosp, Dept Neurosurg, Kumamoto, Japan
[12] Ono Pharmaceut Co LTD, Dept Clin Dev, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7548
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
    Song, Yuqin
    Gao, Quanli
    Zhang, Huilai
    Fan, Lei
    Zhou, Jianfeng
    Zou, Dehui
    Li, Wei
    Yang, Haiyan
    Liu, Ting
    Wang, Quanshun
    Lv, Fangfang
    Guo, Haiyi
    Zhao, Xia
    Wang, Dan
    Zhang, Pei
    Wang, Yidi
    Wang, Lei
    Liu, Tengfei
    Zhang, Yun
    Shen, Zhirong
    Huang, Jane
    Zhu, Jun
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1147 - 1156
  • [42] Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma
    Hayashi, H.
    Okada, M.
    Kijima, T.
    Aoe, K.
    Kato, T.
    Fujimoto, N.
    Nakagawa, K.
    Takeda, Y.
    Hida, T.
    Kanai, K.
    Hirano, J.
    Namba, Y.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1076 - S1076
  • [43] Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis
    Lauer, Eliza M.
    Waterhouse, Miguel
    Braig, Moritz
    Mutter, Jurik
    Bleul, Sabine
    Duque-Afonso, Jesus
    Duyster, Justus
    Marks, Reinhard
    Reinacher, Peter C.
    Prinz, Marco
    Illerhaus, Gerald
    Finke, Juergen
    Schorb, Elisabeth
    Scherer, Florian
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (02) : E110 - E114
  • [44] NovaSure impedance controlled system for endometrial ablation: Three-year follow-up on 107 patients
    Gallinat, A
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (05) : 1585 - 1589
  • [45] Primary hyperparathyroidism: Effect of parathyroidectomy on regional bone mineral density in Danish patients: A three-year follow-up study
    Christiansen, P
    Steiniche, T
    Brixen, K
    Hessov, I
    Melsen, F
    Heickendorff, L
    Mosekilde, L
    BONE, 1999, 25 (05) : 589 - 595
  • [46] Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
    Nagane, Motoo
    Narita, Yoshitaka
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2019, 134
  • [47] Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
    Jain, Preetesh
    Romaguera, Jorge
    Srour, Samer A.
    Lee, Hun J.
    Hagemeister, Frederick
    Westin, Jason
    Fayad, Luis
    Samaniego, Felipe
    Badillo, Maria
    Zhang, Liang
    Nastoupil, Lorreta
    Kanagal-Shamanna, Rashmi
    Fowler, Nathan
    Wang, Michael L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (03) : 404 - 411
  • [48] A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis
    Kato, Koji
    Fujii, Nobuharu
    Makita, Shinichi
    Goto, Hideki
    Kanda, Junya
    Shimada, Kazuyuki
    Akashi, Koichi
    Izutsu, Koji
    Teshima, Takanori
    Fukuda, Natsuko
    Sumitani, Tokuhito
    Nakamura, Shota
    Sumi, Hiroyuki
    Shimizu, Shinji
    Kakurai, Yasuyuki
    Yoshikawa, Kenji
    Tobinai, Kensei
    Usui, Noriko
    Hatake, Kiyohiko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (03) : 409 - 420
  • [49] A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis
    Koji Kato
    Nobuharu Fujii
    Shinichi Makita
    Hideki Goto
    Junya Kanda
    Kazuyuki Shimada
    Koichi Akashi
    Koji Izutsu
    Takanori Teshima
    Natsuko Fukuda
    Tokuhito Sumitani
    Shota Nakamura
    Hiroyuki Sumi
    Shinji Shimizu
    Yasuyuki Kakurai
    Kenji Yoshikawa
    Kensei Tobinai
    Noriko Usui
    Kiyohiko Hatake
    International Journal of Hematology, 2023, 117 : 409 - 420
  • [50] Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kriachok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Wang, Min Hui
    Yu, Ting
    Ghia, Paolo
    BLOOD, 2021, 138
12345